LUXEMBOURG & MELBOURNE, Australia--(BUSINESS WIRE)--ABL, S.A. and Evivar Medical Pty Ltd today announced the completion of agreements to cross-licence their respective intellectual property portfolios and to form strategic alliances based on the use of their proprietary disease management platforms in HIV and Hepatitis (namely TherapyEdge, ViroScore and SeqHepB).The agreements will include joint strategies in development and commercialisation of their products, and joint research efforts to develop new products.